Compassionate Use of Gemtuzumab Ozogamicin (Mylotarg) for Treatment of Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL)

Trial Profile

Compassionate Use of Gemtuzumab Ozogamicin (Mylotarg) for Treatment of Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL)

Suspended
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Gemtuzumab ozogamicin (Primary)
  • Indications Acute myeloid leukaemia; Acute promyelocytic leukaemia
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Most Recent Events

    • 13 Apr 2017 Status changed from recruiting to suspended.
    • 18 Aug 2014 The minimum age of subjects to be included in the study is changed from 3 months to 18 years as reported by ClinicalTrials.gov.
    • 21 Jul 2014 Planned primary completion date changed from 1 Aug 2015 to 1 Aug 2020 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top